Human BSEP Vesicle Kit (HEK293-derived)

Why is BSEP inhibition assessed differently from other DDI transporters such as P-gp or BCRP?

Unlike P-gp and BCRP — where both substrate and inhibitor status of the investigational drug are evaluated — BSEP assessment in the regulatory context focuses primarily on inhibition. This is because BSEP’s physiological role is highly specific: it is the dominant canalicular efflux transporter for conjugated bile salts in hepatocytes, and its inhibition by a drug causes intracellular bile acid accumulation, leading to cholestatic liver injury (DILI). A drug is rarely a BSEP substrate itself; the clinical concern is whether it inhibits BSEP-mediated bile acid efflux in patients. FDA (2017) and EMA (2013) guidance therefore recommend BSEP inhibition IC₅₀ determination using the vesicular transport assay with taurocholate as the probe substrate as the primary in vitro DILI risk screen.

Which probe substrate is used for BSEP vesicular transport inhibition assays?

Taurocholate (TCA, taurocholic acid) is the standard probe substrate for BSEP vesicular transport assays, used in radiolabelled form (³H-taurocholate) in the majority of regulatory DDI studies. Taurocholate is a primary conjugated bile acid, a physiological BSEP substrate, and is cited in both FDA and EMA guidance as the reference probe. Taurolitocholate-3-sulfate (TLCS) is used as an alternative probe substrate when taurocholate transport signal is insufficient. For fluorescence-based detection, fluorescent bile acid analogues compatible with the Cell4Pharma assay format are available. The kit is compatible with all standard probe substrates and detection methods.

What IC₅₀ threshold is considered clinically relevant for BSEP inhibition?

Regulatory agencies do not specify a single fixed IC₅₀ cut-off for BSEP inhibition; rather, BSEP inhibition data are interpreted in the context of total hepatic drug concentration versus the measured IC₅₀. A commonly applied risk classification framework (Dawson et al., Toxicol Sci 2012) defines IC₅₀ values below 25 µM as potentially relevant for drugs with hepatic exposure, particularly when combined with clinical cholestatic signals or elevated ALP/bilirubin in preclinical studies. The key regulatory output is the IC₅₀ value and the relationship between systemic and hepatic drug exposure — not a binary pass/fail threshold. The Cell4Pharma BSEP kit enables precise IC₅₀ determination across a full concentration range, which is the data format expected in DILI risk characterization packages for NDA/MAA submissions.

Are cat and dog BSEP vesicle kits available, and when are they needed?

Yes — Cell4Pharma offers cat and dog BSEP vesicle kits alongside the human kit, available via SeamlessBio on request. Comparative BSEP inhibition studies across species are used in two scenarios: first, in veterinary drug safety assessment where the target species is a companion animal and human BSEP data alone are insufficient; and second, in preclinical DILI species translation, where discordance between rat and dog cholestatic signals is investigated through direct species comparison of BSEP inhibition potency. BSEP amino acid sequence and substrate specificity differ across species, so human IC₅₀ values do not always predict dog or cat BSEP sensitivity — making species-specific kits the appropriate tool when cross-species DILI characterization is required.

Can the BSEP vesicle kit be used as part of a broader ABC transporter DDI panel?

Yes — BSEP is routinely assessed as part of a complete hepatic transporter DDI panel alongside P-gp (ABCB1), BCRP (ABCG2), and MRP2 (ABCC2). While P-gp, BCRP, and MRP2 are assessed for both substrate and inhibitor potential of the investigational drug, BSEP is assessed for inhibition only. Cell4Pharma’s ABC transporter vesicle kit range — P-gp, BCRP, BSEP, MRP1, MRP2, MRP5 — shares a common assay format and buffer system, enabling parallel processing within the same experiment and reducing total assay development time. The Human Control Vesicle Kit (C4PVK009) serves as the single matched negative control across all transporter assays in the panel. All kits are available via SeamlessBio for the DACH region.